As previously discussed regarding the issue of tumor heterogeneity, driver gene mutations are homogeneous within a pancreatic ductal adenocarcinoma [17], thus even if a second lesion derived from a minor molecular subclone it will still have the same KRAS mutation as the primary tumor sample. The gene discussed is KRAS; the disease is neoplasm.